Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for cancer and other serious diseases. Founded in 2003, the company has made significant strides in the oncology sector, particularly with its proprietary drug discovery platform that targets specific molecular pathways. With a strong presence in the US and expanding operations globally, Deciphera is renowned for its core product, ripretinib, which offers a unique approach to treating gastrointestinal stromal tumours (GIST). The company’s commitment to advancing precision medicine has positioned it as a notable player in the industry, achieving key milestones such as successful clinical trials and regulatory approvals. Deciphera Pharmaceuticals continues to drive innovation, aiming to improve patient outcomes through its cutting-edge therapies.
DitchCarbon Score
How does Deciphera Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Deciphera Pharmaceuticals's score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Deciphera Pharmaceuticals's reported carbon emissions
Deciphera Pharmaceuticals, headquartered in the US, currently does not have publicly available data on its carbon emissions, as there are no reported figures for emissions in kg CO2e. Additionally, there are no specified reduction targets or climate commitments outlined in their initiatives. This lack of data suggests that the company may still be in the early stages of developing a comprehensive climate strategy or reporting framework. As the pharmaceutical industry increasingly prioritises sustainability, it will be important for Deciphera to establish clear climate commitments and emissions reduction goals to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Deciphera Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
